^
+ Follow VARDENAFIL Tag
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1515060
                    [Title] => Intimate questions about love and sex
                    [Summary] => 

Recently, I have been getting many questions regarding love, sex, and impotence.

[DatePublished] => 2015-10-26 10:00:00 [ColumnID] => 134789 [Focus] => 0 [AuthorID] => 1805275 [AuthorName] => Dr. Willie T. Ong [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) [1] => Array ( [ArticleID] => 264734 [Title] => Wonder-drug designed for sexual wellness [Summary] => The truth about male sexuality is hard to swallow.
[DatePublished] => 2004-09-14 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => 1804862 [AuthorName] => Igan D’Bayan [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) [2] => Array ( [ArticleID] => 242151 [Title] => New treatment for erectile difficulty bared [Summary] => A new treatment for erectile dysfunction or erection difficulty (ED) – a condition that affects an estimated 152 million men worldwide – was recently introduced by Bayer AG of Germany and GlaxoSmithKline (GSK).

Vardenafil, marketed by Bayer Philippines Inc. and GSK Philippines Inc., has been proven in many clinical trials worldwide to be a safe and reliable treatment for ED, a condition that plagues over half of all men above age 40.
[DatePublished] => 2004-03-11 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [3] => Array ( [ArticleID] => 152317 [Title] => Giant German pharma set to launch newest anti-"ED" preparation [Summary] => Leverkusen, Germany - First Pivotal Phase III data for vardenafil, Bayer’s new, highly selective phosphodiesterase-5 inhibitor for erectile dysfunction (ED), show statistically significant improvements in erectile function and consistency in response among up to 85 percent of the broad population of men treated. The data was presented last December at the Annual Meeting of the Sexual Medicine Society of North America (SMSNA) in Charleston, South Carolina/USA.
[DatePublished] => 2002-03-01 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) ) )
VARDENAFIL
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1515060
                    [Title] => Intimate questions about love and sex
                    [Summary] => 

Recently, I have been getting many questions regarding love, sex, and impotence.

[DatePublished] => 2015-10-26 10:00:00 [ColumnID] => 134789 [Focus] => 0 [AuthorID] => 1805275 [AuthorName] => Dr. Willie T. Ong [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) [1] => Array ( [ArticleID] => 264734 [Title] => Wonder-drug designed for sexual wellness [Summary] => The truth about male sexuality is hard to swallow.
[DatePublished] => 2004-09-14 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => 1804862 [AuthorName] => Igan D’Bayan [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) [2] => Array ( [ArticleID] => 242151 [Title] => New treatment for erectile difficulty bared [Summary] => A new treatment for erectile dysfunction or erection difficulty (ED) – a condition that affects an estimated 152 million men worldwide – was recently introduced by Bayer AG of Germany and GlaxoSmithKline (GSK).

Vardenafil, marketed by Bayer Philippines Inc. and GSK Philippines Inc., has been proven in many clinical trials worldwide to be a safe and reliable treatment for ED, a condition that plagues over half of all men above age 40.
[DatePublished] => 2004-03-11 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [3] => Array ( [ArticleID] => 152317 [Title] => Giant German pharma set to launch newest anti-"ED" preparation [Summary] => Leverkusen, Germany - First Pivotal Phase III data for vardenafil, Bayer’s new, highly selective phosphodiesterase-5 inhibitor for erectile dysfunction (ED), show statistically significant improvements in erectile function and consistency in response among up to 85 percent of the broad population of men treated. The data was presented last December at the Annual Meeting of the Sexual Medicine Society of North America (SMSNA) in Charleston, South Carolina/USA.
[DatePublished] => 2002-03-01 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) ) )
abtest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

Get Updated:

Signup for the News Round now

FORGOT PASSWORD?
SIGN IN
or sign in with